Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines - Sentinel Lymph Node Biopsy

The presentation discusses the role and historical significance of Sentinel Lymph Node Biopsy (SLNB) in managing primary cutaneous melanoma, emphasizing its importance as a gold standard for pathologic staging. The speaker acknowledges that while SLNB is a straightforward procedure, its utility in clinical practice continues to evolve. Sourcing back to its introduction over 30 years ago, SLNB remains critical for assessing the risk of metastasis and determining subsequent treatment options. Key studies such as MSLT 1 and MSLT 2 underline the prognostic value of the biopsy, showing that a positive result significantly decreases melanoma-specific survival. However, there remains ambiguity regarding the role of adjuvant therapies, as many trials have focused on improving relapse-free survival without strong evidence for overall survival benefits. Emerging data including the use of nomograms and gene expression profiles for determining SLNB's necessity are presented, but their effectiveness is still under scrutiny. Updated NCCN guidelines emphasize the importance of assessing risk over staging, advising that patients with less than 10% risk may not require SLNB. The speaker concludes that ongoing trials and research are vital for improving treatment strategies in melanoma and that a positive lymph node biopsy necessitates careful discussion with medical oncologists regarding adjuvant therapy options.